Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Businesswire·2025-12-05 09:15公司核心动态 - 百时美施贵宝的Breyanzi获得美国FDA批准，成为首个且唯一用于治疗复发或难治性边缘区淋巴瘤成人患者的CAR T细胞疗法 [1] 行业与产品里程碑 - 此次批准标志着CAR T细胞疗法在边缘区淋巴瘤治疗领域取得了重大突破，为该患者群体提供了新的治疗选择 [1] - Breyanzi是首个在该适应症上获得批准的CAR T细胞疗法，确立了公司在特定血液肿瘤领域的领先地位 [1]